In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PMA PHARMACEUTICAL OUTCOMES PLANNING INCLUDES EFFORT TO ADDRESS MEASUREMENT OF "DISADVANTAGED CONDITIONS": SEPTEMBER MEETING WILL REVIEW ASSESSMENT TOOLS

Executive Summary

The Pharmaceutical Manufacturers Association is preparing to evaluate current performance measures that could be used as the foundation for a system to assess the quality of pharmaceutical care. Approximately 50-70 individuals suggested by PMA member companies are expected to participate in a Sept. 8-9 meeting in Washington, D.C. on the status of current measurement tools. The meeting will be the second this year held by the association to anticipate developments in the field of outcomes assessment and to try to ensure that the methods adopted in the future account for pharmaceutical treatments.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS024416

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel